

Castanea Sativa, *Arnica montana*, *Hedera Helix* *Geranium maculatum*), triamcinolone acetonide, a topical irritant (e.g., anthralin) or sensitizer (e.g., squaric acid dibutyl ester [SADBE] or diphenyl cyclopropanone [DPCP]), clomipramine, unsaturated fatty acids (e.g., gamma linolenic acid), a fatty acid derivative, a thickener (such as, e.g., carbomer, glycol distearate, cetearyl alcohol), a hair loss concealer, niacin, nicotinate esters and salts, adenosine, methionine, an androgen receptor inhibitor, a copper peptide, a compound with superoxide dismutation activity, an agent that increases nitric oxide production (e.g., arginine, citrulline, nitroglycerin, amyl nitrite, or sildenafil (Viagra)), a compound that mobilizes bone marrow-derived stem cells (e.g., growth factors such as G-CSF and/or chemical agents such as plerixafor (Mozobil®)), a compound that regulates the differentiation of stem cells into gender-specific specialized human hair follicles (e.g., finasteride, fluconazole, spironolactone, flutamide, diazoxide, 11 α -hydroxyprogesterone, ketoconazole, RU58841, dutasteride, fluridil, or QLT-7704, an antiandrogen oligonucleotide, cyoctol, topical progesterone, topical estrogen, cyproterone acetate, ru58841, combination 5 α -reductase inhibitors, oral contraceptive pills), an antiestrogen, an estrogen, or estrogenlike drug, an anti-oxidants (e.g., glutathione, ascorbic acid, tocopherol, uric acid, or polyphenol antioxidants), inhibitors of reactive oxygen species (ROS) generation (e.g., superoxide dismutase inhibitors; stimulators of ROS breakdown, such as selenium; mTOR inhibitors, such as rapamycin; or sirtuins or activators thereof, such as resveratrol, or other SIRT1, SIRT3 activators, or nicotinamide inhibitors), an agent that induces an immune response or causes inflammation (e.g., tetanus toxoid, topical non-specific irritants (anthralin), or sensitizers (squaric acid dibutyl ester [SADBE] and diphenyl cyclopropanone [DPCP]), and an antiapoptotic compound.

10. The method of claim 1, wherein the CCM composition further comprises Minoxidil.

11. The method of claim 10, wherein Minoxidil is present at a concentration from about 0.5% to about 5% by weight.

12-16. (canceled)

17. The method of claim 1, wherein the CCM composition further comprises bimatoprost.

18. The method of claim 17, wherein bimatoprost is present at a concentration from about 0.01% to about 5% by weight.

19-23. (canceled)

24. The method of claim 1 wherein the CCM composition further comprises penetration enhancers.

25. (canceled)

26. The method of claim 1, wherein the CCM composition is adapted for topical application to mammalian skin as a

foam, wherein said foam comprises bimatoprost and/or Minoxidil, and at least one surfactant, wherein the surfactant optionally includes a foam stabilizer; an aqueous-alcohol solvent, and wherein said aqueous-alcohol solvent comprises water and an alcohol.

27. (canceled)

28. A method of stimulating hair, nail or lash growth and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject comprising contacting the hair (scalp), nail or lash or adjacent areas thereof with a CCM composition produced by the method of claim 1 under conditions that allow for hair, nail or lash growth and/or promoting hair follicle development and/or activation or stimulation on an area of the skin in the subject.

29. The method of claim 28, wherein the scalp, dermis or hair follicle is contacted with the composition.

30. A topical pharmaceutical composition comprising Minoxidil, growth factors and/or a CCM produced by the method of claim 1 and at least one or more pharmaceutically acceptable excipients.

31-33. (canceled)

34. The topical pharmaceutical composition of claim 30, wherein Minoxidil is present at a concentration from about 0.5% to about 5% by weight.

35. The topical pharmaceutical composition of claim 34, wherein Minoxidil is present at a concentration of about 1%, 2% or 5% by weight.

36. (canceled)

37. A topical pharmaceutical composition comprising bimatoprost, growth factors and/or a CCM produced by the method of claim 1 and at least one or more pharmaceutically acceptable excipients.

38. (canceled)

39. The composition of claim 37, wherein bimatoprost is present at a concentration from about 0.01% to about 5% by weight.

40. The composition of claim 39, wherein bimatoprost is present at a concentration of about 0.1%, 1%, 3% or 5% by weight.

41. (canceled)

42. The method of claim 1, wherein the cells are fibroblasts.

43-44. (canceled)

45. The method of claim 1, wherein the cells are grown on beads.

46. The method of claim 1, wherein the cells are grown on mesh.

47-48. (canceled)

* * * * *